Bleeding because of impaired platelet function is a major side effect of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback